Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Saf. 2008 Nov;7(6):771-81. doi: 10.1517/14740330802423291 .

Safety of peginterferon in the treatment of chronic hepatitis C.

Author information

  • 1Thomas Jefferson University, Division of Gastroenterology and Hepatology, Philadelphia, PA, USA.

Abstract

BACKGROUND:

Combination of 'pegylated' interferons (IFNs) plus ribavirin, the standard treatment of chronic hepatitis C (CHC), is frequently associated with side effects. Anticipation, recognition and proper management of these side effects are important to ensure compliance with therapy and achievement of sustained virologic response.

OBJECTIVE:

To illustrate the side effect profile of pegIFN-alpha in the treatment of CHC.

METHODS:

Studies and abstracts were identified through a computerized, English language literature search. Key search terms included peginterferon and CHC. Information available only in abstract form was retrieved from national and international hepatology associations.

RESULTS:

Most adverse events occurring with combination therapy can be anticipated and managed appropriately; therefore, premature discontinuation of therapy owing to side effects is not required in most patients.

PMID:
18983223
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk